Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines

Stéphane Vu (), Marion Bertrand, Marie-Joelle Jabagi, Jérémie Botton, Jérôme Drouin, Bérangère Baricault, Alain Weill, Rosemary Dray-Spira and Mahmoud Zureik
Additional contact information
Stéphane Vu: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Marion Bertrand: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Marie-Joelle Jabagi: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Jérémie Botton: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Jérôme Drouin: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Bérangère Baricault: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Alain Weill: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Rosemary Dray-Spira: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
Mahmoud Zureik: (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract Cases of myocarditis and pericarditis have been reported following the receipt of Covid-19 mRNA vaccines. As vaccination campaigns are still to be extended, we aimed to provide a comprehensive assessment of the association, by vaccine and across sex and age groups. Using nationwide hospital discharge and vaccine data, we analysed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 and 30 (95% CI, 21 to 43) for the mRNA-1273 vaccine. The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-31401-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31401-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-31401-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().